(Q39156092)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Panagiotis J Vlachostergios

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eleana Hatzidaki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Christina D Befani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Christos N Papandreou

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

5 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1169-1181

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-013-9968-1

29 February 2020

exact match

0 references

cites work

Current concepts and management of glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Cytoplasmic sequestration of an O6-methylguanine-DNA methyltransferase enhancer binding protein in DNA repair-deficient human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Bortezomib in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Oxygen-dependent and -independent regulation of HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9968-1

A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.

21 January 2018

1 reference

12 December 2020

p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor

1 reference

12 December 2020

O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry

1 reference

12 December 2020

p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells

1 reference

12 December 2020

Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells

1 reference

12 December 2020

Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways

1 reference

12 December 2020

Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene

1 reference

12 December 2020

Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling

1 reference

12 December 2020

Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone

1 reference

12 December 2020

10.1007/S10637-013-9968-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645448%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference